Zara Baloch, Observer at HCA Houston Healthcare, shared a post on LinkedIn:
“One defining conversation from ASCO Breakthrough 2026 with Dr. Yan Leyfman, MD.
From affordability and accessibility to the expanding role of ctDNA, MRD-guided clinical decision-making, and treatment escalation versus de-escalation, Dr. Yan Leyfman shares his key insights from this year’s meeting in Singapore and where he sees oncology heading next.
Watch the full 90-second conversation.
Hosts: Dr. Adeena Musheer, MBBS , Dr. Zara Baloch.”
Other articles about ASCO on OncoDaily.